Emergent BioSolutions (NYSE: EBS) CFO reports unexercised option expirations

Rhea-AI Filing Summary

Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported the expiration of two employee stock option awards. Stock options for 20,321 shares and 19,963 shares expired unexercised pursuant to their terms, and the footnotes state that no value was received upon expiration.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LINDAHL RICHARD S

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
H	Employee Stock Option (Right to buy)	20,321	$0.00	--
H	Employee Stock Option (Right to buy)	19,963	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to buy) — 0 shares (Direct)

Footnotes (1)

1. The reported stock options expired unexercised pursuant to their terms and no value was received. Vested in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021. Vested in three equal installments beginning on the day prior to the first anniversary of the date of grant, subject to continued service with the company.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDAHL RICHARD S

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$48.33	05/07/2025		H(1)			19,963	(2)	05/07/2025	Common Stock	19,963	$0	0	D
Employee Stock Option (Right to buy)	$61.01	02/25/2026		H(1)			20,321	(3)	02/25/2026	Common Stock	20,321	$0	0	D

Explanation of Responses:

1. The reported stock options expired unexercised pursuant to their terms and no value was received.

2. Vested in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021.

3. Vested in three equal installments beginning on the day prior to the first anniversary of the date of grant, subject to continued service with the company.

Remarks:

This Form 4 was filed late due to an inadvertent administrative error. The Company will report all late Form 4s in its next proxy statement.

	/s/ Richard S. Lindahl	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Emergent BioSolutions (EBS) disclose about Richard S. Lindahl’s stock options?

Emergent BioSolutions disclosed that CFO Richard S. Lindahl had two employee stock option grants expire unexercised. One covered 20,321 shares and the other 19,963 shares, and the related footnote clarifies that no value was received when these options expired under their original terms.

Were any Emergent BioSolutions (EBS) shares bought or sold in this Form 4 filing?

No shares were bought or sold in this Form 4. The transactions reported relate solely to the expiration and cancellation of employee stock options, which lapsed unexercised, and the footnotes explicitly state that no value was received upon these expirations by the reporting executive.

How many Emergent BioSolutions (EBS) options expired for CFO Richard S. Lindahl?

Two blocks of employee stock options expired for Richard S. Lindahl. One grant covered 20,321 shares and the other 19,963 shares. Both were reported as expirations or cancellations of long derivative positions, and they lapsed without being exercised according to the terms of the option awards.

Did Richard S. Lindahl receive any value from the expired Emergent BioSolutions (EBS) options?

According to the footnotes, Richard S. Lindahl received no value from the expired stock options. They state that the reported stock options expired unexercised pursuant to their terms and that no value was received, indicating these awards ceased without generating cash or shares for the executive.

What type of securities were involved in the Emergent BioSolutions (EBS) Form 4 for Richard S. Lindahl?

The Form 4 involves employee stock options, described as a right to buy Emergent BioSolutions common stock. These derivative securities were long option positions that ultimately expired or were canceled without exercise, so they did not convert into underlying common shares for the reporting executive.